Phase II Study of Intravenous Rexin-G in Osteosarcoma

Summary

Rexin-G is a tumor-targeted gene medicine that is designed to seek out and destroy both primary tumors and metastatic cancers without the side effects of standard chemotherapy. The objectives of the study are: (1) to evaluate the clinical effectiveness of intravenous injections of Rexin-G, a tumor-targeted gene vector, in controlling tumor growth and prolonging life, and (2) to evaluate its over-all safety.

Timeline

Start

2007-12

Primary completion

2010-07

Completion

2011-06

Drugs

Indications